Q-omics provides the consensus-scored IFI27 profile across patient tissues and cancer cell-line models. IFI27 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IFI27 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, IFI27 RNA expression shows 15,508 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where IFI27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFI27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFI27 survival associations across molecular data types. IFI27 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFI27 RNA expression–survival associations across cancer types. High IFI27 expression shows unfavorable associations in HNSC, ACC, UVM, PAAD and THYM, but favorable associations in SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IFI27 RNA expression.
This table summarizes IFI27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IFI27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFI27 shows lower tumor expression in LUSC and higher tumor expression in HNSC, KIRC, BLCA, KIRP and BRCA. The HNSC box plot shows higher IFI27 RNA expression in tumor versus normal tissue (log2 FC = +4.163, t-test p < 0.001).
This table shows molecular features associated with IFI27 in patient tissues and cancer cell lines. In patient samples, IFI27 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFI27 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
